Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Biolase Inc (BIOL)

Biolase Inc (BIOL)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0174 -0.0447 (-71.98%) 10/02/24 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.0174 unch (unch) -
News & Headlines for Wed, Oct 2nd, 2024
Biolase: Q3 Earnings Snapshot

Biolase: Q3 Earnings Snapshot

BIOL : 0.0174 (-71.98%)
Biolase: Q2 Earnings Snapshot

Biolase: Q2 Earnings Snapshot

BIOL : 0.0174 (-71.98%)
Biolase: Q1 Earnings Snapshot

Biolase: Q1 Earnings Snapshot

BIOL : 0.0174 (-71.98%)
Biolase: Q4 Earnings Snapshot

Biolase: Q4 Earnings Snapshot

BIOL : 0.0174 (-71.98%)
Biolase: Q3 Earnings Snapshot

Biolase: Q3 Earnings Snapshot

BIOL : 0.0174 (-71.98%)
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

/PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the closing of its previously...

BIOL : 0.0174 (-71.98%)
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

/PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the pricing of an underwritten...

BIOL : 0.0174 (-71.98%)
Biolase: Q2 Earnings Snapshot

Biolase: Q2 Earnings Snapshot

BIOL : 0.0174 (-71.98%)
BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR

/PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the second quarter ended June 30,...

BIOL : 0.0174 (-71.98%)
BIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023

/PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2023 financial and...

BIOL : 0.0174 (-71.98%)

Barchart Exclusives

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?
Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals